Healthcare Mergers, Acquisitions & Ventures Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions & Ventures Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Antimicrobials
Research from JMI Laboratories Inc. provide new insights into antimicrobials
February 2nd, 2008
Data detailed in 'Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections' have been presented. According to recent research published in the International Journal of Antimicrobial Agents, "The overall expected coverage for tigecycline and selected antimicrobial regimens based upon prevailing susceptibility rates was evaluated for the empirical therapy of complicated skin and skin-structure infections (cSSSIs). Consecutive, non-duplicate bacterial isolates collected from 2000-2005 from patients with...
Source: Healthcare Mergers, Acquisitions & Ventures Week (2008-02-02)
|
|
Advertisement |
|
|
|
